MTHFR rs1801158: What Your Genotype Means
The MTHFR rs1801158 variant is a common genetic polymorphism located in the MTHFR gene. It is primarily studied for its potential influence on how the body processes folate and its debated role in predicting responses to certain chemotherapy medications.
What each genotype means
Typical enzyme activity
This genotype represents the most common form of the MTHFR gene at this position. Research indicates that individuals with this profile typically maintain standard folate metabolism. If you are prescribed fluoropyrimidine-based chemotherapy, discuss your treatment plan with your clinician, as this genotype is considered the baseline for metabolic studies.
This is the most common genotype globally, though frequencies vary significantly by ancestry.
Intermediate enzyme activity
This genotype indicates you carry one copy of the variant allele, which is sometimes referred to as the 677T allele. Studies suggest this may be associated with slightly reduced MTHFR enzyme activity compared to the CC genotype. Please consult your pharmacist or oncologist regarding your specific chemotherapy regimen, as this variant is investigated for its potential role in fluoropyrimidine toxicity.
This genotype is common in many populations, often found in approximately 30% to 50% of individuals depending on ethnic background.
Reduced enzyme activity
This genotype means you carry two copies of the variant allele, which is associated with lower MTHFR enzyme activity and potentially higher homocysteine levels in some individuals. Research has explored this genotype as a potential predictor of increased sensitivity to fluoropyrimidine-based chemotherapy. You should discuss these findings with your healthcare provider to ensure your treatment plan is appropriately managed.
This genotype is less common than the others, typically observed in roughly 5% to 15% of individuals in many populations, though it varies by ancestry.
Understanding the rs1801158 Variant
The rs1801158 variant, often referred to as A1298C, is a single nucleotide polymorphism (SNP) located within the MTHFR gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. For this specific variant, the DNA base adenine (A) is replaced by cytosine (C) at a particular location. This gene provides instructions for making the methylenetetrahydrofolate reductase enzyme, which plays a vital role in the body's one-carbon metabolism pathway. This pathway is essential for converting folate into forms that the body can use for DNA synthesis, repair, and methylation processes. Because this variant is common in many populations, researchers have spent decades investigating whether this change in the genetic code alters the efficiency of the MTHFR enzyme or impacts overall health outcomes.
The Role of the MTHFR Gene
The MTHFR gene encodes the methylenetetrahydrofolate reductase enzyme. This enzyme acts as a gatekeeper in the folate cycle, facilitating the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. This product is necessary for the conversion of the amino acid homocysteine into methionine, which is a building block for proteins and a precursor for S-adenosylmethionine, the body's primary methyl donor. When MTHFR function is reduced, it can theoretically lead to elevated levels of homocysteine in the blood and a decrease in the availability of methyl groups for cellular processes. While the body has compensatory mechanisms to manage these pathways, researchers study variants like rs1801158 to determine if they contribute to subtle metabolic shifts that might influence disease risk or how individuals respond to specific medical treatments.
Research and Clinical Associations
Research into rs1801158 has yielded mixed results regarding its clinical significance. In the context of pharmacogenomics, some studies have explored whether this variant influences the efficacy or toxicity of fluoropyrimidine-based chemotherapy, such as 5-fluorouracil. While some early research suggested a potential link between MTHFR variants and treatment response, other large-scale studies have found no clear predictive value for toxicity. The evidence for this variant is generally considered moderate or inconclusive, as many factors—including diet, overall folate status, and other genetic markers—influence these outcomes. It is important to note that current clinical guidelines for chemotherapy dosing typically prioritize other genes, such as DPYD, rather than MTHFR. Because the scientific community has not reached a consensus on its clinical utility, this variant is not currently used as a standard diagnostic tool for guiding medical therapy.
What You Can and Cannot Do With This Information
Genetic information regarding the MTHFR rs1801158 variant should be interpreted with caution. You cannot use this information to diagnose a medical condition or to make independent decisions about your health, diet, or medication. Because the variant is common and its health impacts are often subtle or dependent on other environmental factors like folate intake, it is not a reliable predictor of disease. If you have received genetic testing results for this variant, do not alter any prescribed medications or supplements based on this information alone. Instead, use these results as a starting point for a conversation with your healthcare provider or a genetic counselor. They can help you understand the context of your results in relation to your overall health history and ensure that any decisions regarding your care are based on established clinical evidence.
How common is this variant?
The rs1801158 variant is common across diverse global populations, though specific allele frequencies vary by ancestry. It is widely considered a common polymorphism in human genetics.
Frequently asked questions
Should I take extra folate if I have the MTHFR rs1801158 variant?
Current public health guidance emphasizes that your overall folate intake is more important than your MTHFR genotype. There is no evidence that individuals with this variant should avoid folic acid or that they require specific supplementation beyond standard dietary recommendations.
Does the MTHFR rs1801158 variant cause health problems?
While some studies have explored associations between this variant and various health conditions, the evidence is often inconsistent or weak. Most experts agree that this variant alone is not a primary cause of disease and should not be used to predict health outcomes.
Is MTHFR testing recommended by doctors?
Routine testing for MTHFR variants is generally not recommended by major medical organizations. Because the results do not typically change clinical management or treatment plans, testing is often considered unnecessary for the general population.
Can this variant affect my chemotherapy treatment?
While some research has investigated the role of MTHFR in chemotherapy response, the results are conflicting and not strong enough to guide clinical practice. Always discuss your specific treatment plan and any genetic concerns with your oncologist or pharmacist.
Sources & further reading
Educational information only, last refreshed 10/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1801158?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in MTHFR
Variant in the MTHFR locus examined in association studies concerning folate metabolism.
MTHFR missense variant (c.1793G>A, p.Arg594Gln) commonly evaluated alongside canonical variants for folate metabolism and hyperhomocysteinemia predisposition.
This SNP is located in the MTHFR gene, which is critical for folate metabolism and often investigated for its role in reproductive health and pregnancy outcomes.
This MTHFR coding variant has been studied as a possible modifier of folate metabolism and homocysteine-related vascular and pregnancy outcomes, though clinical effects are generally small.
Functional polymorphism influencing homocysteine dynamics and vascular endothelial recovery during high-intensity training.
Missense variant influencing folate metabolic pathway activity and baseline plasma homocysteine levels.